What is the efficacy of suzetrigine (Journavx) and what is the recommended prescribing regimen for short‑term treatment of moderate‑to‑severe acute postoperative pain in adults?

Suzetrigine (Journavx): Efficacy and Prescribing

Suzetrigine is an effective non-opioid analgesic for moderate-to-severe acute postoperative pain in adults, prescribed as a 100 mg loading dose followed by 50 mg every 12 hours for up to 14 days, offering comparable pain relief to hydrocodone/acetaminophen with better tolerability and no addiction risk. 1

Efficacy Profile

Suzetrigine demonstrated statistically significant and clinically meaningful pain reduction compared to placebo in two pivotal Phase 3 trials:

• Abdominoplasty trial: Least squares mean difference in SPID48 of 48.4 points (95% CI: 33.6 to 63.1; P < 0.0001) versus placebo 2
• Bunionectomy trial: Least squares mean difference in SPID48 of 29.3 points (95% CI: 14.0 to 44.6; P = 0.0002) versus placebo 2

Pain relief onset was rapid: 119 minutes after abdominoplasty and 240 minutes after bunionectomy for achieving a 2-point reduction in pain scores 2. While suzetrigine did not demonstrate statistical superiority over hydrocodone/acetaminophen 5/325 mg in head-to-head comparison, it provided equivalent analgesic efficacy with significantly fewer adverse events 2, 3.

In real-world open-label studies across diverse surgical and non-surgical acute pain conditions, 83-91% of patients rated suzetrigine's effectiveness as good to excellent, with minimal need for rescue opioids 4.

Prescribing Regimen

Standard dosing 1:

• Loading dose: 100 mg orally on an empty stomach
• Maintenance: 50 mg every 12 hours
• Duration: Up to 14 days or until pain resolution, whichever comes first
• Assessment: Evaluate pain relief within 2-4 hours; supplement with multimodal therapy including opioids if inadequate 5

Clinical Positioning Within Guidelines

The 2022 CDC guidelines emphasize that opioids should not be first-line for many acute pain conditions but acknowledge their role for severe traumatic injuries, invasive surgeries with moderate-to-severe postoperative pain, and when NSAIDs are contraindicated 6. Suzetrigine fits precisely into this treatment gap as a non-opioid alternative for moderate-to-severe acute pain where NSAIDs alone are insufficient but opioid risks are undesirable 1.

The guidelines recommend multimodal analgesia incorporating around-the-clock nonopioid analgesics, noting that systemic opioids are often needed postoperatively but not required in all patients 6. Suzetrigine enables opioid-sparing strategies by providing efficacy comparable to opioids without respiratory depression, sedation, or addiction potential 7, 8.

Mechanism and Safety Advantages

Suzetrigine works by selectively inhibiting voltage-gated sodium channel NaV1.8, which is expressed exclusively in peripheral nociceptors 8. This peripheral-only mechanism means:

• No CNS effects: No sedation, dizziness, or cognitive impairment typical of opioids
• No addiction potential: Does not bind to opioid receptors or other CNS targets 4
• Better tolerability: Meta-analysis showed significantly fewer adverse events versus both placebo (RR: 0.86) and hydrocodone/acetaminophen (RR: 0.81) 3

The most common adverse events were mild-to-moderate nausea and dizziness (71% mild, 8.2% moderate severity), with 89% treatment completion rates versus 75% for placebo 1, 4.

Critical Prescribing Precautions

Drug interactions 1:

• Strong CYP3A inhibitors (ketoconazole, clarithromycin, ritonavir): Contraindicated or require dose adjustment
• Strong CYP3A inducers (rifampin, carbamazepine, phenytoin): May reduce efficacy
• Suzetrigine induces CYP3A and may reduce effectiveness of hormonal contraceptives, though studies showed no clinically significant interaction with ethinyl estradiol/levonorgestrel 1

Special populations:

• Hepatic impairment: Use with caution; dose adjustments may be needed 7
• Renal impairment: M6-SUZ metabolite is a P-gp substrate; monitor in severe renal dysfunction 1
• Pregnancy/fertility: Rat studies showed increased pre-implantation loss at high doses, though uncertain human relevance 1

Administration requirements 5:

• Loading dose must be taken on an empty stomach for optimal absorption
• Maintenance doses can be taken with or without food
• Oral administration only—no IV formulation currently available

Common Pitfalls to Avoid

1. Prior authorization delays: Check insurance requirements before discharge to avoid treatment gaps 5
2. Inadequate pain assessment: Reassess within 2-4 hours; don't hesitate to add opioids if suzetrigine alone is insufficient 5
3. Ignoring drug interactions: Always screen for CYP3A inhibitors/inducers before prescribing 1
4. Exceeding duration limits: Currently approved only for acute pain up to 14 days; chronic pain indications are investigational 5, 4
5. Monotherapy assumption: Suzetrigine works best within multimodal analgesia; continue NSAIDs, acetaminophen, and non-pharmacologic therapies as appropriate 6

Clinical Algorithm

For moderate-to-severe acute postoperative pain in adults:

1. Assess pain severity: NPRS ≥4 and moderate-to-severe on verbal rating scale
2. Screen for contraindications: Strong CYP3A inhibitors, severe hepatic impairment
3. Initiate suzetrigine: 100 mg loading dose (empty stomach), then 50 mg q12h
4. Concurrent therapy: Continue scheduled NSAIDs/acetaminophen; ibuprofen 400 mg q6h PRN as rescue 1
5. Reassess at 2-4 hours: If inadequate relief, add opioids rather than abandoning suzetrigine
6. Duration: Continue up to 14 days or pain resolution
7. Transition: Taper to non-opioid maintenance therapy as pain improves

Suzetrigine represents the first new class of acute pain medication in nearly 30 years 5, offering a peripheral-acting, non-addictive alternative that aligns with CDC recommendations to minimize opioid exposure while maintaining effective analgesia for moderate-to-severe acute pain 6.